Serum autotaxin levels in responders to HCV treatment by direct-acting antivirals
Abstract Background Hepatitis C virus (HCV) infection is considered one of the main causes of chronic liver disease around the world. Liver biopsy has been believed to be the gold standard for the assessment of the degree of liver fibrosis. Thus, there is a need to improve non-invasive evaluation of...
Main Authors: | Nancy Abdel Fattah Ahmed, Ahmed Galal Deiab, Ahmad Shawki Mohammad Hasan, Ahmad Mohamed Yousry Abd Elbaky |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2020-08-01
|
Series: | Egyptian Liver Journal |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s43066-020-00051-x |
Similar Items
-
Effect of sustained virological response after direct-acting antivirals on liver fibrosis in patients with chronic HCV infection
by: Ramy H. Agwa, et al.
Published: (2022-02-01) -
Autotaxin: A Potential biomarker for primary biliary cholangitis
by: Yifei Yang, et al.
Published: (2024-01-01) -
Liver Fibrosis Regression and Associated Factors in HCV Patients Treated with Direct-Acting Antiviral Agents
by: Naim Abu-Freha, et al.
Published: (2023-09-01) -
Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
by: Zulfikar S, et al.
Published: (2020-07-01) -
Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target
by: Konstantinos Ntatsoulis, et al.
Published: (2021-10-01)